Insider tradingForm 4
Tarsus Pharmaceuticals, Inc. (TARS) Insider Trading
9 open-market trades reported since Sep 3, 2026: 0 purchases worth $0 and 9 sales worth $5.19M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| William J. Phd Link | Director | 0 | $0 | 1 | $980K |
| Elizabeth Yeu Lin | Chief Medical Officer | 0 | $0 | 5 | $2.12M |
| Bobak R. Azamian | CEO | 0 | $0 | 2 | $1.71M |
| Seshadri Neervannan | COO | 0 | $0 | 1 | $388K |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Sep 17 | William J. Phd LinkDirector | ▼ SELL10b5-1 | $980K | |
| Sep 9 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $943K | |
| Sep 9 | Bobak R. AzamianCEO | ▼ SELL10b5-1 | $906K | |
| Sep 9 | Seshadri NeervannanCOO | ▼ SELL10b5-1 | $388K | |
| Sep 9 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $278K | |
| Sep 3 | Bobak R. AzamianCEO | ▼ SELL10b5-1 | $801K | |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $431K | |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $340K | |
| Sep 3 | Elizabeth Yeu LinChief Medical Officer | ▼ SELL10b5-1 | $127K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings